Trade

with

Intercept Pharmaceuticals Inc
(NASDAQ: ICPT)
AdChoices
231.33
+6.88
+3.07%
After Hours :
233.55
+2.22
+0.96%

Open

223.93

Previous Close

224.45

Volume (Avg)

511.03k (476.05k)

Day's Range

223.51-239.50

52Wk Range

46.81-497.00

Market Cap.

4.91B

Dividend Rate ( Yield )

-

Beta

-1.46

Shares Outstanding

21.22M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.62M

    • Net Income

    • -67.79M

    • Market Cap.

    • 4.91B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -15,446.58

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -1.46

    • Forward P/E

    • -39.84

    • Price/Sales

    • 2,500.00

    • Price/Book Value

    • 16.92

    • Price/Cash flow

    • -80.65

      • EBITDA

      • -39.35M

      • Return on Capital %

      • -108.15

      • Return on Equity %

      • -126.37

      • Return on Assets %

      • -108.15

      • Book Value/Share

      • 13.66

      • Shares Outstanding

      • 21.22M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 479.25

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -5.87

        • Cashflow Estimate

        • -5.44

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 9.90

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 69.92

            • Pre-Tax Margin

            • -15,446.58

            • 21.84

            • Net Profit Margin

            • -15,446.58

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.32

              • Current Ratio

              • 25.72

              • 1.92

              • Quick Ratio

              • 25.09

              • 1.31

              • Interest Coverage

              • -

              • 17.64

              • Leverage Ratio

              • 1.07

              • 2.03

              • Book Value/Share

              • 13.66

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -15.24

                • 21.74

                • P/E Ratio 5-Year High

                • -38.27

                • 193.96

                • P/E Ratio 5-Year Low

                • -1.38

                • 87.26

                • Price/Sales Ratio

                • 2,500.00

                • 3.68

                • Price/Book Value

                • 14.49

                • 3.66

                • Price/Cash Flow Ratio

                • -80.65

                • 13.76

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -126.37

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -108.15

                    (-)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -126.37

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • -

                  • 2.46

                  • Asset Turnover

                  • 0.01

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -39.45M
                  Operating Margin
                  -2,432.85
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -80.65
                  Ownership

                  Institutional Ownership

                  97.73%

                  Top 10 Institutions

                  82.69%

                  Mutual Fund Ownership

                  42.96%

                  Float

                  46.62%

                  5% / Insider Ownership

                  2.56%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,162,568

                  • 0.00

                  • 5.48

                  • Hansard EU Carmignac Patrimoine

                  •  

                    799,460

                  • 0.00

                  • 3.77

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    606,800

                  • 0.00

                  • 2.86

                  • Hansard EU Carmignac Investissement

                  •  

                    482,406

                  • 0.00

                  • 2.27

                  • Harbor Capital Appreciation Fund

                  •  

                    321,098

                  • 18.21

                  • 1.52

                  • Fidelity® OTC Portfolio

                  •  

                    283,119

                  • 0.00

                  • 1.33

                  • Fidelity® Select Health Care Portfolio

                  •  

                    228,200

                  • 1.02

                  • 1.08

                  • Vanguard Mid-Cap Index Fund

                  •  

                    217,425

                  • 10.84

                  • 1.02

                  • Vanguard Total Stock Mkt Idx

                  •  

                    209,488

                  • 11.36

                  • 0.99

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Genextra SpA

                  •  

                    5,938,890

                  • -17.37%

                  • 30.63

                  • Fidelity Management and Research Company

                  •  

                    3,134,938

                  • +9.85%

                  • 14.80

                  • Orbimed Advisors, LLC

                  •  

                    1,485,324

                  • -10.23%

                  • 7.00

                  • Jennison Associates LLC

                  •  

                    1,427,118

                  • +25.39%

                  • 6.74

                  • Capital World Investors

                  •  

                    736,800

                  • -26.67%

                  • 3.48

                  • Vanguard Group, Inc.

                  •  

                    650,073

                  • +11.95%

                  • 3.07

                  • T. Rowe Price Associates, Inc.

                  •  

                    622,030

                  • +9.58%

                  • 2.94

                  • BlackRock Fund Advisors

                  •  

                    308,817

                  • +30.42%

                  • 1.46

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Distressed

                  Style

                  Mid Growth

                  Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease ut...moreilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is...more developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.lessless

                  Key People

                  Mr. Mark Pruzanski, M.D.

                  CEO/Co-Founder/Director/President

                  Jonathan T. Silverstein

                  Director/Chairman of the Board

                  Ms. Barbara Duncan

                  CFO/Chief Accounting Officer/Treasurer

                  Mr. David Shapiro, M.D.

                  Chief Medical Officer/Executive VP, Divisional

                  Glenn P. Sblendorio

                  Director

                  • Intercept Pharmaceuticals Inc

                  • 450 West 15th Street

                  • New York, NY 10011

                  • USA.Map

                  • Phone: +1 646 747-1000

                  • Fax: +1 646 747-1001

                  • interceptpharma.com

                  Incorporated

                  2002

                  Employees

                  50

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: